Artykuł w czasopiśmie
Brak miniatury
Licencja
CC-BYCC-BY - Uznanie autorstwa
 

Enzyme-triggered- and tumor-targeted delivery with tunable, methacrylated poly(ethylene glycols) and hyaluronic acid hybrid nanogels

Uproszczony widok
cris.lastimport.scopus2024-02-12T19:49:06Z
dc.abstract.enEnzyme-responsive polymeric-based nanostructures are potential candidates for serving as key materials in targeted drug delivery carriers. However, the major risk in their prolonged application is fast disassembling of the short-lived polymeric-based structures. Another disadvantage is the limited accessibility of the enzyme to the moieties that are located inside the network. Here, we report on a modified environmentally responsive and enzymatically cleavable nanogel carrier that contains a hybrid network. A properly adjusted volume phase transition (VPT) temperature allowed independent shrinking of a) poly(ethylene glycol) methyl ether methacrylate (OEGMA) with di(ethylene glycol) and b) methyl ether methacrylate (MEO2MA) part of the network, and the exposition of hyaluronic acid methacrylate (MeHa) network based carboxylic groups for its targeted action with the cellular based receptors. This effect was substantial after raising temperature in typical hyperthermia-based treatment therapies. Additionally, novel tunable NGs gained an opportunity to store- and to efficient-enzyme-triggered release relatively low but highly therapeutic doses of doxorubicin (DOX) and mitoxantrone (MTX). The controlled enzymatic degradation of NGs could be enhanced by introducing more hyaluronidase enzyme (HAdase), that is usually overexpressed in cancer environments. MTT assay results revealed effective cytotoxic activity of the NGs against the human MCF-7 breast cancer cells, the A278 ovarian cancer cells and also cytocompatibility against the MCF-10A and HOF healthy cells. The obtained tunable, hybrid network NGs might be used as a useful platform for programmed delivery of other pharmaceuticals and diagnostics in therapeutic applications.
dc.affiliationUniwersytet Warszawski
dc.contributor.authorZabost, Ewelina
dc.contributor.authorKarbarz, Marcin
dc.contributor.authorStojek, Zbigniew
dc.contributor.authorWałęka-Bargieł, Ewelina
dc.contributor.authorLiwińska, Wioletta
dc.date.accessioned2024-01-24T22:49:28Z
dc.date.available2024-01-24T22:49:28Z
dc.date.copyright2022-08-07
dc.date.issued2022
dc.description.accesstimeAT_PUBLICATION
dc.description.financeŚrodki finansowe, o których mowa w art. 365 pkt. 2 ustawy
dc.description.number1
dc.description.versionFINAL_PUBLISHED
dc.description.volume29
dc.identifier.doi10.1080/10717544.2022.2105443
dc.identifier.issn1071-7544
dc.identifier.urihttps://repozytorium.uw.edu.pl//handle/item/106311
dc.identifier.weblinkhttps://www.tandfonline.com/doi/pdf/10.1080/10717544.2022.2105443
dc.languageeng
dc.pbn.affiliationchemical sciences
dc.relation.ispartofDrug Delivery
dc.relation.pages2561-2578
dc.rightsCC-BY
dc.sciencecloudnosend
dc.subject.enTargeted drug delivery
dc.subject.enenzymatic degradation
dc.subject.encontrolled release
dc.subject.enhybrid network nanogel
dc.subject.enmethacrylated hyaluronic acid
dc.subject.enpoly(ethylene glycol)
dc.titleEnzyme-triggered- and tumor-targeted delivery with tunable, methacrylated poly(ethylene glycols) and hyaluronic acid hybrid nanogels
dc.typeJournalArticle
dspace.entity.typePublication